Dermata Therapeutics, Inc. (DRMA)
USD 1.04
(-5.45%)
USD 1.04
(-5.45%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | -6.4 Million | -8.83 Million | -5.69 Million | -4.02 Million | -3.92 Million |
| Net Income | -7.79 Million | -9.61 Million | -7.9 Million | -3.23 Million | -4.72 Million |
| Depreciation & Amortization | - | - | - | 322.00 | 1355.00 |
| Deferred income taxes | - | - | - | - | -730.96 |
| Stock-based compensation | 522.08 Thousand | 930.32 Thousand | 1.9 Million | - | 730.96 |
| Change in working capital | 863.67 Thousand | -153.57 Thousand | 289.55 Thousand | -755.84 Thousand | -74.98 Thousand |
| Other non-cash items | 522.08 Thousand | 930.32 Thousand | 14.12 Thousand | -36.48 Thousand | 872.71 Thousand |
| Investing Cash Flow | - | - | - | - | - |
| Investments in PPE | - | - | - | - | - |
| Acquisitions | - | - | - | - | - |
| Investment purchases | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - |
| Financing Cash Flow | 7.6 Million | 4.27 Million | 15.96 Million | 2.56 Million | 4.73 Million |
| Debt repayment | - | - | -556.48 Thousand | -810.18 Thousand | -776.16 Thousand |
| Dividends payments | - | - | - | - | - |
| Common Stock Repurchased | -40.00 | - | -1 Million | - | - |
| Common Stock Issuance | 7.6 Million | 4.27 Million | 15.38 Million | 268.75 Thousand | 5.36 Million |
| Other Financing Activities | 147 Thousand | 4276.65 | 2.13 Million | 3.1 Million | 150 Thousand |
| Accounts receivables | - | - | - | - | - |
| Accounts payables | 369.32 Thousand | -18.54 Thousand | 410.96 Thousand | -232.9 Thousand | 122.42 Thousand |
| Inventory | - | - | - | - | - |
| Other working capital | 494.35 Thousand | -135.03 Thousand | -121.41 Thousand | -522.93 Thousand | -197.4 Thousand |
| Cash at beginning of period | 6.24 Million | 10.79 Million | 530.4 Thousand | 1.99 Million | 1.17 Million |
| Cash at end of period | 7.43 Million | 6.24 Million | 10.79 Million | 530.4 Thousand | 1.99 Million |
| Capital Expenditure | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - |
| Net cash flow / Change in cash | 1.19 Million | -4.55 Million | 10.26 Million | -1.46 Million | 812.18 Thousand |
| Free Cash Flow | -6.4 Million | -8.83 Million | -5.69 Million | -4.02 Million | -3.92 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -2.82 Million | -3.13 Million | -7.79 Million | -2.13 Million | -1.71 Million | -1.7 Million |
| Depreciation & Amortization | - | - | - | - | - | - |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 19.6 Thousand | 587.23 Thousand | 522.08 Thousand | 128.46 Thousand | 131.17 Thousand | 131.17 Thousand |
| Change in working capital | 683.54 Thousand | -157.42 Thousand | 863.67 Thousand | 858.2 Thousand | -183.59 Thousand | -270.17 Thousand |
| Other non-cash items | 19.6 Thousand | 587.23 Thousand | 522.08 Thousand | 128.46 Thousand | 131.17 Thousand | 131.17 Thousand |
| Investing Cash Flow | - | - | - | - | - | - |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | 2.33 Million | - | 7.6 Million | 1.95 Million | -35.41 Thousand | 1.51 Million |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | -828.00 | - | -40.00 | 75.42 | -35.42 | - |
| Common Stock Issuance | 2.34 Million | - | 7.6 Million | 1.95 Million | -35.41 Thousand | 1.51 Million |
| Other Financing Activities | 2.34 Million | - | 147 Thousand | 1953.96 | 35.42 | 34.00 |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | 403.73 Thousand | -43.48 Thousand | 369.32 Thousand | 391.57 Thousand | 36.68 Thousand | -55.09 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | 683.54 Thousand | -157.42 Thousand | 494.35 Thousand | 466.63 Thousand | -220.27 Thousand | -215.08 Thousand |
| Cash at beginning of period | 4.73 Million | 7.43 Million | 6.24 Million | 6.63 Million | 8.43 Million | 8.76 Million |
| Cash at end of period | 4.94 Million | 4.73 Million | 7.43 Million | 7.43 Million | 6.63 Million | 8.43 Million |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | 213.41 Thousand | -2.7 Million | 1.19 Million | 806.65 Thousand | -1.8 Million | -328.22 Thousand |
| Free Cash Flow | -2.12 Million | -2.7 Million | -6.4 Million | -1.14 Million | -1.77 Million | -1.84 Million |
TROX
000678
CCBC
120110
301160
SLVMF